^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ADP-TILIL7
i
Other names: ADP-TILIL7
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Adaptimmune
Drug class:
Immunostimulant, IL-7 modulator
Related drugs:
4ms
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Inge Marie Svane
New P1 trial • Metastases
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • ADP-TILIL7
2years
Next-Generation, Inducible IL-7-Expressing, Tumor-Infiltrating Lymphocytes by Lentiviral Vector Genetic Modification for Clinical Application (ASGCT 2022)
However, T-cells are incapable of producing their own IL-7 and rely on secretion from surrounding stromal cells.11 We hypothesize that the introduction of an inducible IL-7 gene to TILs (next generation TIL; ADP-TILIL7) will improve their ability to engraft, proliferate, and survive, while maintaining diverse TIL specificity...Nat Rev Immunol. 2011;11(5):330.
Clinical • Tumor-Infiltrating Lymphocyte
|
MAGEA4 (Melanoma antigen family A, 4) • IL7 (Interleukin 7) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
ADP-TILIL7
Share via
